Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer

Kuramoto, Tomomi; Inagaki, Takeshi; Fujii, Reona; Sasaki, Yumiko; Nishizawa, Satoshi; Nanpo, Yoshihito; Matusmura, Nagahide; Kohjimoto, Yasuo; Hara, Isao

doi:10.1007/s10147-012-0463-z

Cited by 8 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported that visceral metastases, including lung, liver and lymph nodes and excluding bone, and pretreatment anemia (hemoglobin < 11.3 g/dL) were two independent factors predicting overall survival in patients who received docetaxel chemotherapy for prostate cancer [ 13 ]. In a previous study, we collected the data from not only our hospital but also our related hospitals.…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundWhile novel drugs have been developed, docetaxel remains one of the standard initial systemic therapies for castration-resistant prostate cancer (CRPC) patients. Despite the excellent anti-tumor effect of docetaxel, its severe adverse effects sometimes distress patients. Therefore, it would be very helpful to predict the efficacy of docetaxel before treatment. The aims of this study were to evaluate the potential value of patient characteristics in predicting overall survival (OS) and to develop a risk classification for CRPC patients treated with docetaxel-based chemotherapy.MethodsThis study included 79 patients with CRPC treated with docetaxel. The variables, including patient characteristics at diagnosis and at the start of chemotherapy, were retrospectively collected. Prognostic factors predicting OS were analyzed using the Cox proportional hazard model. Risk stratification for overall survival was determined based on the results of multivariate analysis.ResultsPSA response ≥50 % was observed in 55 (69.6 %) of all patients, and the median OS was 22.5 months. The multivariate analysis showed that age, serum PSA level at the start of chemotherapy, and Hb were independent prognostic factors for OS. In addition, ECOG performance status (PS) and the CRP-to-albumin ratio were not significant but were considered possible predictors for OS. Risk stratification according to the number of these risk factors could effectively stratify CRPC patients treated with docetaxel in terms of OS.ConclusionsAge, serum PSA level at the start of chemotherapy, and Hb were identified as independent prognostic factors of OS. ECOG PS and the CRP-to-albumin ratio were not significant, but were considered possible predictors for OS in Japanese CRPC patients treated with docetaxel. Risk stratification based on these factors could be helpful for estimating overall survival.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although no associated lethal adverse effects were observed during this study, this possibility cannot be ignored, and prophylactic anticoagulant agents may therefore be prescribed to patients who have a history of, or who are at risk of, cardiovascular toxicity (19). However, Qi et al (20) concluded that the survival rates with regard to PSA response rate were not improved with the addition of estramustine to docetaxel-based chemotherapy (4). Therefore, the toxicity profile must be considered prior to the addition of estramustine to the therapeutic regimen.…”

Section: Discussionmentioning

confidence: 99%

“…PCa initially grows in an androgen-dependent manner, and therefore, androgen deprivation therapy (ADT) may improve symptoms and reduce PSA levels in ~80% of metastatic PCa patients (3). After an average of two years undergoing hormone therapy, the majority of metastatic PCa cases are likely to develop into castration-resistant PCa (CRPC) (4). Chemotherapy for CRPC was implemented for a number of years, although it had limited efficacy, until two landmark randomized control trials were reported.…”

Section: Introductionmentioning

confidence: 99%

“…Chemotherapy for CRPC was implemented for a number of years, although it had limited efficacy, until two landmark randomized control trials were reported. Once complete, the two phase III trials demonstrated that a docetaxel-based combined chemotherapy regimen may improve survival rates in CRPC patients (3,4). In the TAX 327 study, the median overall survival (OS) time was improved in the docetaxel plus prednisone treatment group compared with the mitoxantrone plus prednisone treatment group (3).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical predictor of survival following docetaxel-based chemotherapy

Lee

Huang

et al. 2014

Oncology Letters

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common type of cancer in males in the USA and the incidence is increasing. For castration-resistant PCa (CRPC), previous studies have identified docetaxel-based chemotherapy as the first-line therapy. In the present study, the efficacy of docetaxel-based chemotherapy was investigated in a population of patients with CRPC. This study included 26 individuals (mean age, 73 years) with CRPC who were patients between July 2007 and October 2012 at the Kaohsiung Medical University Hospital (Kaohsiung, Taiwan). The regimen consisted of intravenous docetaxel (70 mg/m2) once every four weeks plus oral prednisolone (5 mg) twice daily for five days. Prostate-specific antigen (PSA) response (defined as a PSA decrease of >50% over four weeks), time to PSA progression, PCa-specific survival and overall survival (OS) were evaluated. For these 26 patients, the mean PSA level prior to chemotherapy treatment was 335.58 ng/ml. During follow-up, the average number of cycles of chemotherapy was approximately seven and 15 patients (58%) achieved a PSA response. PSA response was found to significantly correlate with OS and PCa-specific survival (P=0.014 and P=0.028, respectively). The mean value of the PSA nadir level was 89.97 ng/ml and time to PSA nadir was five months. The most common adverse event was leucopenia, which affected 88% of the patients. The results indicated that the length of time to PSA nadir and the occurrence of leucopenia may impact the PSA response. The docetaxel-based chemotherapy was a feasible and effective treatment regimen in patients with CRPC. However, the occurrence of adverse events, particularly the high incidence of leucopenia, may be cause for concern.

show abstract

“…Moreover, estramustine has been shown to trigger apoptosis [1,4,5]. Side effects of treatment with combinations containing estramustine include anemia [6,7,8,9,10], which is a risk factor of patient survival [11]. …”

Section: Introductionmentioning

confidence: 99%

Estramustine-Induced Suicidal Erythrocyte Death

Bissinger

Modicano

Frauenfeld

et al. 2013

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: The nitrogen mustard derivative of estradiol-17β-phosphate estramustine is used for the treatment of prostate cancer. Estramustine may trigger suicidal death of cancer cells. Side effects of estramustine include anemia. At least in theory, estramustine could cause anemia by stimulation of eryptosis, the suicidal death of erythrocytes. Hallmarks of eryptosis include cell shrinkage, increased cytosolic Ca²⁺ activity ([Ca²⁺]), ceramide formation and phosphatidylserine translocation to the outer leaflet of the cell membrane with phosphatidylserine exposure at the erythrocyte surface. Eryptosis is stimulated by increase of cytosolic Ca²⁺ activity ([Ca²⁺]_i). The present study explored whether estramustine triggers eryptosis. Methods: [Ca²⁺]_i was estimated from Fluo3 fluorescence, cell volume from forward scatter, phosphatidylserine exposure from annexin V binding, and hemolysis from hemoglobin release. Results: A 24 h exposure to estramustine (≤ 100 µM) significantly increased [Ca²⁺]_i, increased annexin V binding and increased hemoglobin release. The effect of estramustine on annexin V binding was significantly blunted by removal of extracellular Ca²⁺. Conclusions: Estramustine stimulates both, eryptosis and hemolysis. The estramustine induced translocation of phosphatidylserine to the cell surface is at least partially due to increase of cytosolic Ca²⁺ activity.

show abstract

Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer

Cited by 8 publications

References 15 publications

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

Clinical predictor of survival following docetaxel-based chemotherapy

Estramustine-Induced Suicidal Erythrocyte Death

Contact Info

Product

Resources

About